PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics (NASDAQ: PTCT) has granted stock options for 75,085 shares and 33,740 restricted stock units (RSUs) to 79 new employees as a part of their compensation package. Approved on April 13, 2021, these inducement grants comply with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $47.31, based on the stock's closing price on the grant date. The vesting period spans four years, with a portion vesting annually and quarterly, contingent on continued employment.
- Inducement grants potentially attract talent, enhancing workforce capabilities.
- Stock options and RSUs align employee interests with shareholder value.
- Dilution risk from granting stock options and RSUs to new hires.
SOUTH PLAINFIELD, N.J., April 19, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2021 it approved non-statutory stock options to purchase an aggregate of 75,085 shares of its common stock and 33,740 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 79 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation.
The inducement grants were approved by PTC's Compensation Committee on April 13, 2021 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
All stock option awards have an exercise price of
About PTC Therapeutics, Inc.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.
For More Information:
Investors:
Kylie O'Keefe
+1 (908) 300-0691
kokeefe@ptcbio.com
Media:
Jane Baj
+1 (908) 912-9167
jbaj@ptcbio.com
View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301271221.html
SOURCE PTC Therapeutics, Inc.
FAQ
What stock options did PTC Therapeutics grant to new employees?
When were the stock options approved by PTC Therapeutics?
What is the exercise price of the stock options granted by PTC Therapeutics?
How long do the stock options of PTC Therapeutics last?